78
Views
11
CrossRef citations to date
0
Altmetric
CASE REPORT

Successful treatment of protein-losing enteropathy due to AA amyloidosis with octreotide in a patient with rheumatoid arthritis

, , , , &
Pages 406-411 | Received 28 Mar 2012, Accepted 08 May 2012, Published online: 02 Jan 2014

REFERENCES

  • Umar SB, DiBaise JK. Protein-losing enteropathy: case illustra-tions and clinical review. Am J Gastroenterol. 2010;105:43-9 (quiz 50).
  • Fushimi T, Takahashi Y, Kashima Y, et al. Severe protein losing enteropathy with intractable diarrhea due to systemic AA amy-loidosis, successfully treated with corticosteroid and octreotide. Amyloid. 2005;12:48–53.
  • Mei:lini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349: 583–96.
  • Khan MF, Falk RH. Amyloidosis. Postgrad Med J. 2001;77: 686–93.
  • Nakamura T, Amyloid A. Amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments. Clin Exp Rheumatol. 2011;29:850–7.
  • Ishii W, Kishida D, Suzuki A, et al. A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept. Rheumatol Int. 2011;31:247–50.
  • Narvaez J, Hernandez MV, Ruiz JM, Vaquero CG, Juanola X, Nollaa JM. Rituximab therapy for AA-amyloidosis secondary to rheumatoid arthritis. Joint Bone Spine. 2011;78:101–3.
  • Lee HL, Han DS, Kim JB, Jeon YC, Sohn JH, Hahm JS. Suc-cessful treatment of protein-losing enteropathy induced by intestinal lymphangiectasia in a liver cirrhosis patient with octreotide: a case report. J Korean Med Sci. 2004;19:466–9.
  • Yam LT, Oropilla SB. Octreotide for diarrhea in amyloidosis. Ann Intern Med. 1991;115:577.
  • Jeong YS, Jun JB, Kim TH, et al. Successful treatment of protein-losing enteropathy due to AA amyloidosis with somatostatin analogue and high dose steroid in ankylosing spondylitis. Clin Exp Rheumatol. 2000;18:619–21.
  • Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol. 2001;13:67–73.
  • Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71.
  • Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24–9.
  • Gomez-Casanovas E, Sanmarti R, Sole M, Canete JD, Munoz-Gomez J. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum. 2001;44:66–72.
  • Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Sus-ceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum. 2009;61:1435–40.
  • Wakhlu A, Krisnani N, Hissaria P, Aggarwal A, Misra R. Prev-alence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis. J Rheumatol. 2003;30:948–51.
  • Koivuniemi R, Paimela L, Suomalainen R, Tornroth T, Leirisalo-Repo M. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid. 2008;15:262–8.
  • Okuda Y, Takasugi K, Oyama T, Onuma M, Oyama H. Amy-loidosis in rheumatoid arthritis-clinical study of 124 histologi-cally proven cases. Ryumachi. 1994;34: 939–46.
  • Ebert EC, Nagar M. Gastrointestinal manifestations of amyloi-dosis. Am J Gastroenterol. 2008;103:776–87.
  • Suzuki C, Higaki S, Nishiaki M, et al. 99mTc-HSA-D scintig-raphy in the diagnosis of protein-losing gastroenteropathy due to secondary amyloidosis. J Gastroenterol. 1997;32:78–82.
  • Okuda Y, Takasugi K, Oyama T, Oyama H, Nanba S, Miyamoto T. Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis. Ann Rheum Dis. 1997;56:535–41.
  • Kuroda T, Otaki Y, Sato H, et al. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with inf-liximab. Rheumatol Int. 2008;28:1155–9.
  • Yazici Y, Erkan D, Levine DM, Parker TS, Lockshin MD. Pro-tein-losing enteropathy in systemic lupus erythematosus: report of a severe, persistent case and review of pathophysiology. Lupus. 2002;11:119–23.
  • Bhattacharya S, Vijayasekar C, Worlding J, Mathew G. Octreo-tide in chemotherapy induced diarrhoea in colorectal cancer: a review article. Acta Gastroenterol Belg. 2009;72:289–95.
  • Szilagyi A, Shrier I. Systematic review: the use of somatostatin or octreotide in refractory diarrhoea. Aliment Pharmacol Ther. 2001;15:1889–97.
  • Kubba AK, Dallal H, Haydon GH, Hayes PC, Palmer KR. The effect of octreotide on gastroduodenal blood flow measured by laser Doppler flowmetry in rabbits and man. Am J Gastroenterol. 1999;94:1077–82.
  • Reubi JC, Laissue JA, Waser B, Steffen DL, Hipkin RW, Schonbrunn A. Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts. J Clin Endocrinol Metab. 1999;84:2942–50.
  • Elliott DE, Li J, Blum AM, Metwali A, Patel YC, Weinstock JV. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol. 1999;29:2454–63.
  • Karalis K, Mastorakos G, Sano H, Wilder RL, Chrousos GP. Somatostatin may participate in the antiinflammatory actions of glucocorticoids. Endocrinology. 1995;136:4133–8.
  • Paran D, Elkayam 0, Mayo A, et al. A pilot study of a long acting somatostatin analogue for the treatment of refractory rheumatoid arthritis. Ann Rheum Dis. 2001;60:888–91.
  • Hachulla E, Grateau G. Diagnostic tools for amyloidosis. Joint Bone Spine. 2002;69:538–45.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.